These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36794598)

  • 1. Optimal delivery strategies for nanoparticle-mediated mRNA delivery.
    Li X; Guo X; Hu M; Cai R; Chen C
    J Mater Chem B; 2023 Mar; 11(10):2063-2077. PubMed ID: 36794598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nano delivery systems and applications of mRNA.
    Li M; Li Y; Li S; Jia L; Wang H; Li M; Deng J; Zhu A; Ma L; Li W; Yu P; Zhu T
    Eur J Med Chem; 2022 Jan; 227():113910. PubMed ID: 34689071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid nanoparticles for mRNA delivery.
    Hou X; Zaks T; Langer R; Dong Y
    Nat Rev Mater; 2021; 6(12):1078-1094. PubMed ID: 34394960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
    Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
    Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
    Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines.
    Wu Y; Yu S; de Lázaro I
    Nanoscale; 2024 Apr; 16(14):6820-6836. PubMed ID: 38502114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Nanocarrier-Based mRNA Therapy: Challenges and Promise for Clinical Transformation.
    Li W; Wang C; Zhang Y; Lu Y
    Small; 2024 Jul; 20(28):e2310531. PubMed ID: 38287729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling mRNA delivery bottlenecks of ineffective delivery vectors by co-transfection with effective carriers.
    Oude Egberink R; van Schie DM; Joosten B; de Muynck LTA; Jacobs W; van Oostrum J; Brock R
    Eur J Pharm Biopharm; 2024 Sep; 202():114414. PubMed ID: 39009193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.
    Ho W; Gao M; Li F; Li Z; Zhang XQ; Xu X
    Adv Healthc Mater; 2021 Apr; 10(8):e2001812. PubMed ID: 33458958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging mRNA technologies: delivery strategies and biomedical applications.
    Xiao Y; Tang Z; Huang X; Chen W; Zhou J; Liu H; Liu C; Kong N; Tao W
    Chem Soc Rev; 2022 May; 51(10):3828-3845. PubMed ID: 35437544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer.
    Lin Y; Chen X; Wang K; Liang L; Zhang H
    Vaccines (Basel); 2024 Jun; 12(7):. PubMed ID: 39066365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of mRNA for regulating functions of immune cells.
    Shi J; Huang MW; Lu ZD; Du XJ; Shen S; Xu CF; Wang J
    J Control Release; 2022 May; 345():494-511. PubMed ID: 35337940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency.
    Forster Iii J; Nandi D; Kulkarni A
    Biomater Sci; 2022 Sep; 10(19):5566-5582. PubMed ID: 35971974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
    Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
    Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyphenolic Nanoparticle Platforms (PARCELs) for
    Ma Y; Tiwade PB; VanKeulen-Miller R; Narasipura EA; Fenton OS
    Nano Lett; 2024 May; 24(20):6092-6101. PubMed ID: 38728297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems.
    Li J; Zhang Y; Yang YG; Sun T
    Mol Pharm; 2024 Aug; 21(8):3743-3763. PubMed ID: 38953708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.
    Labouta HI; Langer R; Cullis PR; Merkel OM; Prausnitz MR; Gomaa Y; Nogueira SS; Kumeria T
    Drug Deliv Transl Res; 2022 Nov; 12(11):2581-2588. PubMed ID: 35290656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.